精神病临床高危个体神经认知功能:系统综述与Meta分析
该研究基于78项独立研究(5162例CHR-P、2865例健康对照、486例FEP)进行系统综述与Meta分析,发现CHR-P个体在多个神经认知任务上较健康对照存在中到大效应损害,且纵向转化为精神病与CVLT任务的中到大效应损害相关;Meta回归发现年龄和教育对处理速度有显著影响。结论支持神经认知功能障碍可作为CHR-P的潜在检测与预后生物标志物。
要点
- CHR-P个体在Stroop色词阅读、HVLT-R、数字符号编码等任务较健康对照存在中到大效应损害。
- CHR-P个体的神经认知损害程度轻于首次发作精神病(FEP)个体。
- 纵向转化为精神病与CVLT任务的中到大效应损害相关(g=-0.58)。
核心结论
- Meta分析结果支持神经认知功能障碍可作为CHR-P个体的潜在检测与预后生物标志物。
研究设计与样本
- 系统综述与Meta分析,检索Web of Science、Cochrane Central Register of Reviews、Ovid/PsycINFO及试验注册库至2020年7月1日。
- 共纳入78项独立研究,含5162例CHR-P个体、2865例健康对照和486例FEP个体。
- 采用随机效应模型Meta分析,评估发表偏倚与研究质量,并进行Meta回归。
主要发现
- 较健康对照,CHR-P个体在Stroop色词阅读任务上显示大效应损害(g=-1.17;95%CI,-1.86至-0.48)。
- 较健康对照,CHR-P个体在HVLT-R任务上显示中到大效应损害(g=-0.86;95%CI,-1.43至-0.28)。
- 较健康对照,CHR-P个体在数字符号编码测试上显示中到大效应损害(g=-0.74;95%CI,-1.19至-0.29)。
- CHR-P个体的神经认知损害程度轻于FEP个体。
- 纵向转化为精神病与CVLT任务的中到大效应损害相关(g=-0.58;95%CI,-1.12至-0.05)。
关键数值与推荐
- 神经认知任务按7个MATRICS域和8个CHR-P域进行聚类。
- 主要效应量指标为Hedges g,比较CHR-P与健康对照、FEP或按纵向转化分层。
- Meta回归发现年龄和教育对处理速度有显著效应。
临床怎么用
- 神经认知评估或可辅助CHR-P的早期检测与预后判断。
- 关注处理速度、言语学习和执行功能等域的综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Neurocognitive functioning is a potential biomarker to advance detection, prognosis, and preventive care for individuals at clinical high risk for psychosis (CHR-P). The current consistency and magnitude of neurocognitive functioning in individuals at CHR-P are undetermined. OBJECTIVE: To provide an updated synthesis of evidence on the consistency and magnitude of neurocognitive functioning in individuals at CHR-P. DATA SOURCES: Web of Science database, Cochrane Central Register of Reviews, and Ovid/PsycINFO and trial registries up to July 1, 2020. STUDY SELECTION: Multistep literature search compliant with Preferred Reporting Items for Systematic Reviews and Meta-analyses and Meta-analysis of Observational Studies in Epidemiology performed by independent researchers to identify original studies reporting on neurocognitive functioning in individuals at CHR-P. DATA EXTRACTION AND SYNTHESIS: Independent researchers extracted the data, clustering the neurocognitive tasks according to 7 Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) domains and 8 CHR-P domains. Random-effect model meta-analyses, assessment of publication biases and study quality, and meta-regressions were conducted. MAIN OUTCOMES AND MEASURES: The primary effect size measure was Hedges g of neurocognitive functioning in individuals at CHR-P (1) compared with healthy control (HC) individuals or (2) compared with individuals with first-episode psychosis (FEP) or (3) stratified for the longitudinal transition to psychosis. RESULTS: A total of 78 independent studies were included, consisting of 5162 individuals at CHR-P (mean [SD; range] age, 20.2 [3.3; 12.0-29.0] years; 2529 [49.0%] were female), 2865 HC individuals (mean [SD; range] age, 21.1 [3.6; 12.6-29.2] years; 1490 [52.0%] were female), and 486 individuals with FEP (mean [SD; range] age, 23.0 [2.0; 19.1-26.4] years; 267 [55.9%] were female). Compared with HC individuals, individuals at CHR-P showed medium to large deficits on the Stroop color word reading task (g = -1.17; 95% CI, -1.86 to -0.48), Hopkins Verbal Learning Test-Revised (g = -0.86; 95% CI, -1.43 to -0.28), digit symbol coding test (g = -0.74; 95% CI, -1.19 to -0.29), Brief Assessment of Cognition Scale Symbol Coding (g = -0.67; 95% CI, -0.95 to -0.39), University of Pennsylvania Smell Identification Test (g = -0.55; 95% CI, -0.97 to -0.12), Hinting Task (g = -0.53; 95% CI, -0.77 to -0.28), Rey Auditory Verbal Learning Test (g = -0.50; 95% CI, -0.78 to -0.21), California Verbal Learning Test (CVLT) (g = -0.50; 95% CI, -0.64 to -0.36), and National Adult Reading Test (g = -0.52; 95% CI, -1.01 to -0.03). Individuals at CHR-P were less impaired than individuals with FEP. Longitudinal transition to psychosis from a CHR-P state was associated with medium to large deficits in the CVLT task (g = -0.58; 95% CI, -1.12 to -0.05). Meta-regressions found significant effects for age and education on processing speed. CONCLUSIONS AND RELEVANCE: Findings from this meta-analysis support neurocognitive dysfunction as a potential detection and prognostic biomarker in individuals at CHR-P. These findings may advance clinical research and inform preventive approaches.
引用
- Catalan A, Salazar de Pablo G, Aymerich C, et al. Neurocognitive Functioning in Individuals at Clinical High Risk for Psychosis: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021. PMID: 34132736. doi:10.1001/jamapsychiatry.2021.1290
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。